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Summary
Muir-Torre syndrome (MTS) is an autosomal dominant
disease defined by the coincidence of at least one seba-
ceous skin tumor and one internal malignancy. About
half of MTS patients are affected by colorectal cancer.
In a subgroup of MTS patients the disease has an un-
derlying DNA mismatch-repair (MMR) defect and thus
is allelic to hereditary nonpolyposis colorectal cancer
(HNPCC). The purpose of this study was to examine to
what extent germ-line mutations in DNA MMR genes
are the underlying cause of the MTS phenotype. We
ascertained 16MTS patients with sebaceous skin tumors
and colorectal cancer, and we examined their skin and
visceral tumors for microsatellite instability. All the pa-
tients exhibited high genomic instability in at least one
tumor. The search for germ-line mutations in the
hMSH2 and hMLH1 genes in 13 of the MTS patients
revealed truncating mutations in 9 (69%): eight muta-
tions in the hMSH2 gene and one in the hMLH1 gene.
This is the first systematic search for germ-linemutations
in patients ascertained on the basis of sebaceous skin
tumors. Our results indicate that (1) MTS patients ex-
hibit significantly more mutations in the hMSH2 gene
than in the hMLH1 gene; and (2) the subpopulation of
MTS patients who are also affected by colorectal cancer,
irrespective of family history and age at onset of tumors,
may have a likelihood for an underlying DNA MMR
defect similar to that for patients with a family history
fulfilling the strict clinical criteria for HNPCC.
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Introduction
Autosomal dominantMuir-Torre syndrome (MTS;MIM
158320) is defined by the combined occurrence of at
least one sebaceous skin tumor and one internal malig-
nancy in the same patient (for a review, see Cohen et al.
1991; Schwartz and Torre 1995). Approximately 150
patients have been reported in the literature, so far. The
sebaceous skin tumors include sebaceous adenomas,
epitheliomas, and carcinomas. The spectrum of internal
cancers in MTS is similar to that in hereditary nonpoly-
posis colorectal cancer (HNPCC, or Lynch syndrome;
MIM 120435 and 120436). The most common internal
malignancy is colorectal cancer, accounting for ∼50%
of all primary cancers in MTS. Approximately 15% of
femaleMTS patients develop endometrial cancer (Cohen
et al. 1991).
Patients with MTS also were found in families with
HNPCC. Hence, it has been postulated that some cases
of MTS may represent the more full phenotypic ex-
pression of HNPCC (Lynch et al. 1981). HNPCC is
caused by a germ-line mutation in one of at least five
DNA mismatch-repair (MMR) genes—namely, hMSH2,
hMLH1, hPMS1, or hPMS2 (for a review, see Papa-
dopoulos and Lindblom 1997; Peltoma¨ki and Vasen
1997) or hMSH6/GTBP (Miyaki et al. 1997). This con-
dition predisposes to genetic instability (microsatellite
instability [MIN]) in tumor tissue. In HNPCC families,
1150 different germ-line mutations in the five MMR
genes have been reported. The large majority of these
mutations are almost equally distributed among the two
genes hMSH2 and hMLH1 (Liu et al. 1996; Papado-
poulos and Lindblom 1997; Peltoma¨ki and Vasen 1997;
Wehner et al. 1997; Wijnen et al. 1997). So far, only
weak evidence for a genotype-phenotype correlation has
been found (Vasen et al. 1996; Ja¨ger et al. 1997; Pa-
padopoulos and Lindblom 1997).
Honchel et al. (1994) detected MIN in cutaneous and
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internal tumor tissues from 6 of 13 MTS patients. Con-
sequently, they suggested that MTS consists of two sub-
groups, one of which is allelic to HNPCC. However,
these patients were not examined for germ-line muta-
tions in MMR genes. With regard to MTS families, only
seven germ-line mutations in MMR genes have been
published, all but one of which affect the hMSH2 gene
(Hall et al. 1994; Kolodner et al. 1994; Liu et al. 1994;
Bapat et al. 1996; Kruse et al. 1996; Esche et al. 1997).
The purpose of this study was to examine to what
extent germ-line mutations in DNA MMR genes are the
underlying cause of the MTS phenotype. We therefore
extended our previous molecular genetic examination of
2 MTS patients (Kruse et al. 1996) and examined 14
additional MTS patients, for MMR defects. The patients
had been ascertained on the basis of sebaceous skin tu-
mors and colorectal cancer, irrespective of family history
and age at onset of tumors.
Patients and Methods
Patient Selection
A total of 16 patients with the clinical diagnosis of
MTS were ascertained on the basis of sebaceous skin
tumors and colorectal or endometrial cancer. Thirteen
of them were referred to us by dermatologists or path-
ologists, and 3 were known from previous case reports
(Bisceglia and Zenarola 1991; Panday et al. 1993;Hartig
et al. 1995). Tumor tissue and blood samples, as well
as clinical data, were obtained with appropriate in-
formed consent from the patients.
Isolation of Genomic DNA and RNA from Blood
Samples
Genomic DNA was isolated from peripheral blood
(Miller et al. 1988). To isolate RNA, white blood cells
were obtained from 10 ml of EDTA-anticoagulated
blood (within 24 h after sampling) by use of Ficoll (Phar-
macia Biotech), and RNA was extracted by use of the
Trizol reagent (Gibco BRL), in accordance with theman-
ufacturer’s instructions.
Assessment of MIN
Tumor DNA was extracted from microdissected par-
affin-embedded tumor tissue by use of the QIAamp tis-
sue kit (QIAGEN). If no blood sample was available,
surrounding normal tissue was used to extract normal
DNA. Paired normal and tumor DNA were analyzed for
MIN with X11 microsatellite markers—namely, two
poly-A repeats (BAT25 and BAT26) and nine dinucleo-
tide repeats (D2S123, D2S136, D3S1298, D5S346,
D6S470, D16S663, D18S35, D18S37, and D21S171).
The MIN phenotype is detected as an allelic mobility
shift during electrophoretic runs on denaturing gels. A
tumor was defined to exhibit MIN (MIN) if additional
alleles were observed with at least two markers.
Search for Germ-Line Mutations
SSCP analysis and heteroduplex analysis (HD).—All
the exons of the hMLH1 and hMSH2 genes were am-
plified by PCR, by use of the primers described by Ko-
lodner et al. (1994, 1995). PCR products were examined
by SSCP analysis and HD and were visualized by silver
staining, as described elsewhere (Friedl et al. 1993).
Protein truncation test (PTT).—An RNA aliquot was
reverse transcribed with M-MLV reverse transcriptase
and an oligo-dT primer (Gibco BRL). For PCR ampli-
fication, both hMSH2 and hMLH1 cDNA were ampli-
fied in two overlapping segments of 1.2–1.7 kb and were
transcribed and translated in vitro by use of the TNT-
T7 Quick coupled transcription/translation system (Pro-
mega) and 35S-methionin, as described elsewhere (Luce
et al. 1995).
Direct sequencing.—Paired biotinylated and M13-
tailed primers for the hMSH2 and hMLH1 genes (Ko-
lodner et al. 1994, 1995) were used to amplify genomic
DNA sequences. Single-strand DNA obtained with Dyn-
abeads (Dynal) was sequenced with Sequenase 2.0
(Amersham) by use of M13 universal sequencing primer.
Mutations were confirmed by repetition of both the am-
plification and the sequencing steps.
Results
Paraffin-embedded tumor tissues were obtained from
16 unrelated patients with MTS and from two affected
relatives. Fifteen of the index patients had developed at
least one colorectal malignancy. The only MTS patient
without colorectal cancer had an endometrial cancer,
whereas her daughter had developed a colorectal cancer
(table 1(). In four MTS patients (132, 199, MTS-K8,
and MTS-K10), skin tumors had developed before the
visceral malignancy. One of these patients does not have
a relative with cancer. Two patients have a family history
of visceral cancer but do not fulfill the strict Amsterdam
criteria for HNPCC (Vasen et al. 1991). In one MTS
patient (MTS-K2a), the skin and colorectal tumors de-
veloped synchronously. In the remaining 11 MTS pa-
tients, at least one visceral neoplasm was diagnosed be-
fore the manifestation of the characteristic skin lesions.
Twenty-four skin tumors and 7 visceral tumors, from
16 MTS patients, were examined for MIN as the char-
acteristic molecular feature of an MMR defect. At least
1 skin tumor from each patient exhibited MIN, as de-
tected by a minimum of three microsatellite markers (fig.
1 and table 1). All but 1 of all examined tumors were
MIN. Twenty of the 23 MIN skin tumors and all 7
internal tumors showed high instability, with 140% of
the examined markers being unstable (table 1).
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Figure 1 MIN in patients MTS-K10 and MTS-K1a. DNA from
peripheral blood (lanes N) and skin tumor tissues (lane T, sebaceous
epithelioma; lane T1, sebaceous adenoma; and lane T2, sebaceous
epithelioma) was examined by use of microsatellite marker D21S171
and was visualized by autoradiography after separation on a dena-
turing gel.
Thirteen patients were examined for germ-line mu-
tations in the two MMR genes hMSH2 and hMLH1
(table 1). Of the remaining 3 patients, sufficient normal
DNA or RNA was not available for mutation analysis.
In 6 of the 13 patients, mRNA was available, and a
PTTwas performed first. In 3 of these patients, truncated
proteins were observed in the hMSH2 gene. In the re-
maining 10 patients, we screened the entire coding
regions and the exon/intron boundaries of the two genes,
by use of both SSCP analysis and HD. Aberrant patterns
were obtained from an additional 6 patients.
Sequencing revealed eight germ-line mutations (seven
frameshift and one nonsense) in the hMSH2 gene and
one frameshift mutation in the hMLH1 gene (table 1).
All but one of the mutations are unique to our patient
sample. The hMSH2 mutations identified in our MTS
patient sample were distributed over the entire gene
(table 1).
Discussion
We systematically examined 16 MTS patients affected
by cancer of the colorectum or endometrium, for MMR
defects. The patients were ascertained on the basis of
their characteristic skin lesions, irrespective of family
history or early onset of colorectal cancer. In each of
these patients, at least one sebaceous skin tumor exhib-
ited MIN, as detected by a minimum of 40% of the
markers tested, thus fulfilling the criteria for MIN pro-
posed by Bocker et al. (1997). These results are in ac-
cordance with the study by Honchel et al. (1994), who
also found a high instability in sebaceous skin tumors
of MTS patients affected by colorectal cancer.
We used DNA-based and mRNA-based methods to
screen 13 MTS patients for underlying germ-line mu-
tations in the MMR genes hMSH2 and hMLH1 and
identified nine mutations (eight in the hMSH2 gene and
only one in the hMLH1 gene) that are predicted to lead
to a truncated protein. This finding supports the pre-
viously observed predominance of hMSH2 mutations in
MTS. It contrasts with the mutation spectrum in patients
with “pure” HNPCC: in the International Collaborative
Group–HNPCC database, 42 mutations in the hMSH2
gene and 75 in the hMLH1 gene were reported (Pelto-
ma¨ki and Vasen 1997). Another peculiarity was the pre-
ponderance of males with MTS (13 males vs. 3 females,
among the index patients; see table 1), which is in ac-
cordance with previous observations (Schwartz and
Torre 1995).
In 41% of all MTS cases reported so far, the sebaceous
skin tumors preceded or occurred concurrently with the
internal malignancy (Schwartz and Torre 1995). In this
study, skin tumors in 4 (25%) of the 16 MTS patients
were diagnosed earlier than the internal neoplasm, and
the skin and internal tumors in 1 patient were diagnosed
concurrently. For the remaining 11 MTS patients, the
tentative diagnosis of a cancer-predisposition syndrome
was based on dermatological examination and not on
internal tumors or family history. Thus, in a high pro-
portion of patients, skin tumors characteristic of MTS
can serve as premonitory physical stigmata for an un-
derlying cancer predisposition.
A variety of sebaceous skin tumors observed in MTS
patients are distinctive but difficult to classify (Burgdorf
et al. 1986). This is especially true for some large cystic
and nodular lesions, also observed in our patients (table
1), which seem to be marker lesions because, so far, they
have been seen only in patients with MTS.
The unique clinical feature of 15 of our MTS patients
was the occurrence of at least one colorectal carcinoma.
In the study by Honchel et al. (1994), 6 of 9 MTS pa-
tients with colorectal carcinoma and none of the 4 MTS
patients without colorectal carcinoma exhibited MIN.
Considered together, their results and the results of this
study allow the definition of a distinct phenotype pre-
dicted to be MMR defective—that is, a patient with a
skin tumor characteristic of MTS and with a colorectal
carcinoma. This phenotype seems to have the same
power to predict an MMR defect as the Amsterdam
criteria (Vasen et al. 1991). In 9 (69%) of 13 MTS pa-
tients, we detected germ-line mutations in either the
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hMSH2 or the hMLH1 genes, whereas an extensive mu-
tation analysis of HNPCC kindreds revealed a mutation
in these two genes in 31 (64%) of 48 families (Liu et
al. 1996). In conclusion, we present the first systematic
screening for MMR-gene germ-line mutations in MTS
patients. Despite our limited sample size, we postulate
that the mutation-detection rate in the subpopulation of
MTS patients who exhibit a colorectal carcinoma may
be similar to that for HNPCC patients ascertained by
family history, age at onset, and MIN (Liu et al. 1996).
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